{"nctId":"NCT01722266","briefTitle":"Liraglutide in the Treatment of Type 1 Diabetes Mellitus","startDateStruct":{"date":"2012-11-01","type":"ACTUAL"},"conditions":["Type 1 Diabetes"],"count":72,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Liraglutide 1.8mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liraglutide"]},{"label":"Liraglutide 1.2mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liraglutide"]},{"label":"Liraglutide 0.6 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liraglutide"]}],"interventions":[{"name":"Liraglutide","otherNames":["Victoza"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients with type 1 diabetes mellitus: Fasting c-peptide \\< 0.1nmol/l on insulin therapy for more than 12 months with or without history of diabetic ketoacidosis.\n2. Using a continuous glucose monitoring device (CGM) and regularly measuring their blood sugars four times daily\n3. HbA1c of less than 8.5%.\n4. Well versed with carbohydrate counting\n5. Age 18-75 years\n\nExclusion Criteria:\n\n1. Type 1 diabetes for less than 12 months;\n2. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks;\n3. Hepatic disease (transaminase \\> 3 times normal) or cirrhosis;\n4. Renal impairment (serum creatinine \\> 1.5);\n5. HIV or Hepatitis C positive status;\n6. Participation in any other concurrent clinical trial;\n7. Any other life-threatening, non-cardiac disease;\n8. Use of an investigational agent or therapeutic regimen within 30 days of study.\n9. history of pancreatitis\n10. pregnancy\n11. inability to give informed consent\n12. history of gastroparesis\n13. history of medullary thyroid carcinoma or MEN 2 syndrome.\n14. Family history of MEN 2, Family history of medullary thyroid cancer, or familial medullary thyroid cancer\n15. Women of childbearing potential who are not using adequate contraception 16) Women who are pregnant","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Weekly Glucose Concentrations","description":"The primary endpoint of the study is to detect a difference from baseline in mean weekly blood glucose concentrations before and after 12 weeks of treatment in each of the Liraglutide groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"0"},{"groupId":"OG001","value":"-10","spread":"1"},{"groupId":"OG002","value":"-10","spread":"2"},{"groupId":"OG003","value":"-0.3","spread":"2"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c","description":"Change from baseline (week 0) in HbA1c at 12 weeks after treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"0.15"},{"groupId":"OG001","value":"-0.42","spread":"0.15"},{"groupId":"OG002","value":"-0.78","spread":"0.15"},{"groupId":"OG003","value":"-0.26","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline","description":"Change in Body weight in Kg from baseline after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.5"},{"groupId":"OG001","value":"-4.8","spread":"0.7"},{"groupId":"OG002","value":"-5.0","spread":"1.2"},{"groupId":"OG003","value":"-2.7","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Change in Total Insulin Dose From Baseline","description":"Total daily insulin dose = Basal insulin dose plus bolus insulin dose. Change from baseline in Total daily insulin dose at 12 weeks from treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"0.7"},{"groupId":"OG001","value":"-10","spread":"0.5"},{"groupId":"OG002","value":"-12.1","spread":"0.7"},{"groupId":"OG003","value":"-2.8","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change in the Area Under Curve (AUC) of Glucose Following the Meal","description":"Change in the Area Under Curve (AUC0h-5h) of glucose concentration measured following meal challenge of up to 5hrs performed at baseline (week 0) at 12 weeks following treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0"},{"groupId":"OG001","value":"-0.55","spread":"10"},{"groupId":"OG002","value":"-0.55","spread":"10"},{"groupId":"OG003","value":"-0.01","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change in Carbohydrate Intake","description":"Change from baseline (0 week) in Daily Carbohydrate intake (in grams) at 12 weeks after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":"2.6"},{"groupId":"OG001","value":"-46.4","spread":"1.6"},{"groupId":"OG002","value":"-47.6","spread":"2.6"},{"groupId":"OG003","value":"-23.7","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change in Glucagon Concentrations","description":"change from baseline (week 0) in glucagon concentrations following 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"3"},{"groupId":"OG001","value":"9","spread":"6"},{"groupId":"OG002","value":"-6","spread":"9"},{"groupId":"OG003","value":"7","spread":"4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":["Transient Nausea"]}}}